Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience-Reference-Cited by-同舟云学术

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience

Published:2018-12-10 Issue:6 Volume:234 Page:7708-7717
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Pizzuti Laura¹,Giordano Antonio²,Michelotti Andrea³,Mazzotta Marco⁴,Natoli Clara⁵,Gamucci Teresa⁶⁷,Angelis Claudia³,Landucci Elisabetta³,Diodati Lucrezia³,Iezzi Laura⁵,Mentuccia Lucia⁶,Fabbri Agnese⁸,Barba Maddalena¹,Sanguineti Giuseppe⁹,Marchetti Paolo⁴¹⁰,Tomao Silverio¹¹,Mariani Luciano¹²,Paris Ida¹³,Lorusso Vito¹⁴,Vallarelli Simona¹⁴,Cassano Alessandra¹⁵,Aroldi Francesca¹⁵,Orlandi Armando¹⁵,Moscetti Luca¹⁶,Sergi Domenico¹,Sarobba Maria Giuseppina¹⁷,Tonini Giuseppe¹⁸,Santini Daniele¹⁸,Sini Valentina¹⁹,Veltri Enzo²⁰,Vaccaro Angela⁵,Ferrari Laura⁵,Tursi Michele⁴,Tinari Nicola⁴,Grassadonia Antonino⁴,Greco Filippo²¹,Botticelli Andrea²,Verde Nicla²²,Zamagni Claudio²³,Rubino Daniela²³,Cortesi Enrico²⁴,Magri Valentina²⁴,Pomati Giulia²⁴,Scagnoli Simone²⁴,Capomolla Elisabetta²⁵,Kayal Ramy²⁶,Scinto Angelo Fedele²⁷,Corsi Domenico²⁷,Cazzaniga Marina²⁸,Laudadio Lucio²⁹,Forciniti Samantha²⁹,Mancini Maria²⁹,Carbognin Luisa³⁰,Seminara Patrizia¹⁰,Barni Sandro³¹,Samaritani Riccardo³²,Roselli Mario³³,Portarena Ilaria³³,Russo Antonio³⁴^ORCID,Ficorella Corrado³⁵,Cannita Katia³⁵,Carpano Silvia¹,Pistelli Mirco³⁶,Berardi Rossana³⁶,Maria Ruggero³⁷,Sperduti Isabella³⁸,Ciliberto Gennaro³⁹,Vici Patrizia¹^ORCID

Affiliation:

1. Division of Medical Oncology 2 IRCCS Regina Elena National Cancer Institute Rome Italy

2. Department of Clinical and Molecular Medicine “Sapienza” University of Rome, Azienda Ospedaliera Sant'Andrea Rome Italy

3. UO Oncologia Medica I, Ospedale S. Chiara, Dipartimento di Oncologia Dei Trapianti e Delle Nuove Tecnologie, Azienda Ospedaliera Universitaria Pisana Pisa Italy

4. Department of Medical, Oral and Biotechnological Sciences Centro Scienze Dell'Invecchiamento e Medicina Traslazionale‐CeSI‐MeT Chieti Italy

5. Medical Oncology Unit SS Trinità Hospital, Loc. San MarcianoHospital Sora Frosinone Italy

6. Medical Oncology Unit SS Trinità Hospital Sora Italy

7. Medical Oncology Sandro Pertini Hospital Rome Italy

8. Medical Oncology Unit Belcolle Hospital Viterbo Italy

9. Department of Radiation Oncology IRCCS Regina Elena National Cancer Institute Rome Italy

10. Department of Clinical and Molecular Medicine, A Oncology Division “Sapienza” University of Rome Rome Italy

11. Department of Clinical and Molecular Medicine, A Oncology Division La “Sapienza” University of Rome Rome Italy

12. HPV Unit, Department of Gynaecologic Oncology IRCCS Regina Elena National Cancer Institute Rome Italy

13. Gynecology Oncology Unit Catholic University of the Sacred Heart Rome Italy

14. Division of Medical Oncology IRCCS, Giovanni Paolo II Hospital Bari Italy

15. Department of Medical Oncology Catholic University of Sacred Heart Rome Italy

16. Division of Medical Oncology, Department of Oncology and Hematology University Hospital of Modena Modena Italy

17. Division of Medical Oncology Ospedale San Francesco Nuoro Italy

18. Department of Oncology University Campus Biomedico of Rome Rome Italy

19. Oncology Unit ASL Roma 1, Santo Spirito Hospital Rome Italy

20. Division of Medical Oncology Ospedale S. Maria Goretti Latina Italy

21. ASST Fatebenefratelli Sacco PO Fatebenefratelli Department of Oncology Milan Italy

22. Department of Oncology ASST Fatebenefratelli Sacco PO Fatebenefratelli Milan Italy

23. SSD Oncologia Medica “Addarii” S. Orsola‐Malpighi Hospital Bologna Italy

24. Medical Oncology Policlinico Umberto I, Sapienza, University of Rome Rome Italy

25. Medical Oncology Ospedale “Parodi‐Delfino” Colleferro Italy

26. Department of Radiology IRCCS Regina Elena National Cancer Institute Rome Italy

27. Medical Oncology Unit Ospedale San Pietro Fatebenefratelli Rome Italy

28. Oncology Unit ASST Monza Monza Italy

29. Medical Oncology Ospedale F. Renzetti Lanciano Italy

30. Department of Pathology, Surgery and Oncology “Mater Salutis” Hospital, ULSS21 Verona Italy

31. Department of Oncology Oncology Unit, ASST Bergamo Ovest Treviglio Italy

32. Medical Oncology Unit “Regina Margherita” Hospital Rome Italy

33. Medical Oncology Unit, Department of Systems Medicine Tor Vergata Clinical Center University Hospital, Tor Vergata University Hospital Rome Italy

34. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology University of Palermo Palermo Italy

35. Medical Oncology Department S. Salvatore Hospital, University of L'Aquila L'Aquila Italy

36. Azienda Ospedaliero Universitaria Ospedali Riuniti Clinica di Oncologia, Università Politecnica delle Marche Ancona Italy

37. Institute of General Pathology, Catholic University of the Sacred Heart Rome Italy

38. Bio‐statistics Unit IRCCS Regina Elena National Cancer Institute Rome Italy

39. Scientific Direction IRCCS Regina Elena National Cancer Institute Rome Italy

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcp.27832

Reference30 articles.

1. Benefit from palbociclib and fulvestrant based on previous fulvestrant and/or everolimus treatment. Based on a cohort of over 200 patients treated in a French compassionate program;Arnedos M.;San Antonio Breast Cancer Symposium,2017

2. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2- metastatic breast cancer

3. Retrospective assessment of treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR+/HER2–advanced breast cancer enrolled in an early access program;Brufsky A.;San Antonio Breast Cancer Symposium,2018

4. Real world data on use of palbociclib in hormone‐receptor (ER) positive HER2 negative metastatic breast cancer (MBC) among Asian patients;Chiu J.;Annals of Oncolology,2017

5. The impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib;Clifton K. K.;San Antonio Breast Cancer Symposium,2017

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN;Breast Cancer Research and Treatment;2024-04-01

2. Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review;Targeted Oncology;2024-03-28

3. Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review;Targeted Oncology;2023-04-19

4. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China;BMC Cancer;2023-01-30

5. Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients;Oncology & Haematology;2023